Gut Bacteria Rheumatoid Arthritis Research Reveals a Surprising Connection
New research from Mayo Clinic’s Center for Individualized Medicine has found that gut bacteria rheumatoid arthritis links go far deeper than previously understood. Immunologist Veena Taneja, Ph.D., recently published two studies connecting intestinal microbiota to the onset, prediction, and potential prevention of rheumatoid arthritis, one in Genome Medicine and one in Arthritis and Rheumatology.
More than 1.5 million Americans live with rheumatoid arthritis, an autoimmune disorder in which the body mistakenly attacks its own tissues, causing painful swelling in the joints that can erode bone, deform joints, and damage the skin, eyes, heart, lungs, and blood vessels. Despite its prevalence, the processes that trigger the disease remain incompletely understood. These new findings open a promising new avenue for early detection and treatment.
How Gut Bacteria Can Predict Rheumatoid Arthritis
The Genome Medicine study examined rheumatoid arthritis patients, their relatives, and a healthy control group with the goal of identifying a biomarker capable of predicting susceptibility to the disease. Using genomic sequencing technology, researchers found that certain rare bacterial lineages, normally present in very low abundance in healthy individuals, were significantly expanded in patients with rheumatoid arthritis.
This microbial imbalance, or dysbiosis, appears to be a distinguishing feature of the gut bacteria rheumatoid arthritis relationship. Dr. Taneja noted that the ability to identify these specific microbes creates the foundation for a predictive profile that could help physicians identify who is likely to develop the disease before symptoms appear.
Researchers also identified a specific gut microbe, Collinsella, that was associated with the arthritis phenotype in mouse studies. The presence of this bacterium may offer new pathways for early diagnosis and for interventions aimed at reducing microbial imbalance before or during the earliest stages of disease development.
A Probiotic Approach to Treatment With Fewer Side Effects
The second study, published in Arthritis and Rheumatology, explored whether modifying the gut microbiome could reduce rheumatoid arthritis symptoms. Dr. Taneja treated one group of arthritis susceptible mice with Prevotella histicola, a bacterium naturally found in the healthy human gut, and compared outcomes to an untreated group.
Mice treated with Prevotella histicola showed decreased frequency and severity of symptoms, along with fewer inflammatory conditions associated with rheumatoid arthritis. Importantly, the treatment produced fewer side effects than more traditional approaches, including less weight gain and less villous atrophy, a condition that impairs nutrient absorption in the gut.
Because Prevotella histicola is already part of the normal human gut microbiome, researchers believe treatment based on this bacterium is less likely to cause adverse effects. While human trials have not yet been conducted, the immune systems and arthritis patterns in the mouse models closely mimic those in humans, suggesting the findings may translate.
Why the Gut Bacteria Rheumatoid Arthritis Connection Matters
The gut bacteria rheumatoid arthritis research points toward a future in which microbiome profiling becomes a standard part of rheumatology practice. Intestinal microbiota and metabolic signatures could eventually allow clinicians to build individualized predictive profiles, identifying not only who is likely to develop rheumatoid arthritis but also how the disease is likely to progress in a specific patient.
Dr. Taneja described these as exciting discoveries with the potential to personalize treatment in meaningful ways. The research was funded by the Mayo Clinic Center for Individualized Medicine, which supports work aimed at finding treatments compatible with a patient’s unique genetic and biological profile and translating research discoveries into practical clinical applications.
For a comprehensive overview of rheumatoid arthritis, its symptoms, and current treatment options, the Mayo Clinic provides a thorough and accessible resource.
Clinical Research in Rheumatology and Autoimmune Disease
Validating the gut bacteria rheumatoid arthritis connection in human populations will require well designed clinical trials. Moving from promising mouse model data to evidence based human treatment protocols is a process that depends on experienced research sites capable of conducting complex immunology and rheumatology studies.
FOMAT supports clinical research across multiple therapeutic areas through a national network of investigator sites. To explore active studies, visit our patient active studies page. For more health and research content, explore the FOMAT blogs and updates.
thritis